Unknown

Dataset Information

0

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases.

Methods

Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017.

Results

4373 NSCLC patients with brain metastases in 18 studies were involved. Mutated EGFR associated with significantly improved OS compared with wild type. Subgroup analyses suggested that this relationship persisted in studies conducted in Eastern, with retrospective design, with sample size ?500, mean age of patients ?65.0?years, percentage male ConclusionsThis meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC patients with brain metastases.

SUBMITTER: Li WY 

PROVIDER: S-EPMC6375157 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.

Li Wen-Ya WY   Zhao Ting-Ting TT   Xu Hui-Mian HM   Wang Zhen-Ning ZN   Xu Ying-Ying YY   Han Yunan Y   Song Yong-Xi YX   Wu Jian-Hua JH   Xu Hao H   Yin Song-Cheng SC   Liu Xing-Yu XY   Miao Zhi-Feng ZF  

BMC cancer 20190213 1

<h4>Background</h4>The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases.<h4>Methods</h4>Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017.<h4>Results</h  ...[more]

Similar Datasets

Unknown BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR<sup>T790M</sup> mutation.
| S-EPMC7255027 | biostudies-literature
Unknown Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
| S-EPMC7442419 | biostudies-literature
Unknown The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status.
| S-EPMC9458511 | biostudies-literature
Unknown EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.
| S-EPMC5075503 | biostudies-literature
Unknown FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer.
| S-EPMC6301818 | biostudies-literature
Unknown EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis.
| S-EPMC6612652 | biostudies-literature
Unknown Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
| S-EPMC5522255 | biostudies-literature
Unknown Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model.
| S-EPMC5884842 | biostudies-other
Unknown Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
| S-EPMC6993327 | biostudies-literature
Unknown Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
| S-EPMC7390194 | biostudies-literature